What was the primary driver of the significant revenue increase in the first quarter of fiscal year 2002?

The primary driver of the significant revenue increase was the merger with Bergen Brunswig Corporation, which closed on August 29, 2001. This merger substantially expanded the company's scale, particularly within its Pharmaceutical Distribution segment, leading to a 185% year-over-year increase in total revenue.

How is Cencora (formerly AmerisourceBergen) managing the costs and integration related to the merger?

The company is actively managing merger-related costs, expensing approximately $4.7 million in merger costs during the quarter, primarily for integration consulting fees. Furthermore, it has developed integration plans to consolidate its distribution network and eliminate duplicate administrative functions, aiming for approximately $150 million in annual synergies. This includes reducing the number of distribution facilities and associated personnel.

What is the outlook for the company's gross profit margin?

The gross profit margin has seen some pressure, with declines in the Pharmaceutical Distribution segment on a pro forma basis due to changes in customer mix and competitive pricing. While the inclusion of PharMerica, which has higher gross margins, helped overall reported gross profit, the company anticipates continued downward pressures on sell-side gross profit margins and cannot assure that buy-side margin increases will fully offset these declines.

How is the company's liquidity and capital position?

The company maintains a strong liquidity position. As of March 31, 2002, it had approximately $2.0 billion of aggregate availability under its revolving credit facility and receivables securitization facilities. Operating activities generated $231.3 million in cash during the six months ended March 31, 2002, indicating sufficient capital resources for ongoing operations, capital expenditures, and debt servicing.

COR 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (COR), formerly AmerisourceBergen, reported strong revenue growth in its first quarter of fiscal year 2002, driven significantly by the recent merger. Total revenue surged by 185% to $10.9 billion compared to the prior year's quarter. This substantial increase is largely attributable to the integration of Bergen Brunswig Corporation, which significantly expanded the company's scale and market reach within its Pharmaceutical Distribution segment. Despite the revenue surge, the company is actively managing merger-related costs and executing integration plans, including facility consolidations, which are expected to yield significant annual synergies. Investors should note the company's focus on operational efficiencies and margin improvement in the Pharmaceutical Distribution segment, while the PharMerica segment shows steady growth with improving operating income margins, albeit with lower gross margins due to a shift in its business mix. The company's liquidity remains robust, supported by significant availability under its credit facilities and securitization programs.

Key Highlights

1Total revenue increased by 185% year-over-year to $10.9 billion, primarily due to the merger with Bergen Brunswig Corporation.
2Operating income grew by 196% year-over-year to $190.8 million, or 1.97% of operating revenue (excluding merger costs).
3The Pharmaceutical Distribution segment saw significant revenue growth of 180% historically and 17% on a pro forma basis, driven by increased scale and market presence.
4PharMerica segment revenue grew by 6% year-over-year on a pro forma basis, with operating income margins improving.
5The company is actively pursuing merger integration, including plans to reduce distribution facilities from 51 to approximately 30 over three to four years, aiming for $150 million in annual synergies.
6Diluted earnings per share increased by 47% year-over-year to $0.84, or $0.87 excluding merger costs.
7The company maintained strong liquidity, with $2.0 billion in aggregate availability under its revolving credit facility and receivables securitization facilities.

Cencora, Inc. Quarterly Report for Q2 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions